Skip to content

Shenghuang ketong cream in the treatment of herpes zoster (syndromes of liver yure) -2 phase II clinical study

Shenghuang ketong cream in the treatment of herpes zoster (syndromes of liver yure) random, double-blind, placebo-control, multicenter phase II-2 clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16009573
Enrollment
Unknown
Registered
2016-10-24
Start date
2016-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

Treatment Group:Shenghuang Ketong Cream
Control Group:Placebo Cream

Sponsors

Beijing Hospital of Traditional Chinese Medicin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) in accordance with the standards of Western medicine diagnosis of herpes zoster; 2) with the syndrome of liver yure; 3) aged 18~70 years old; 4) skin lesions appear less than 72 h; 5) pain VAS score more than 4 points; 6) voluntarily, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) in the first 1 weeks, the use of the system or local anti-virus drugs; 2) pregnancy, pre-pregnancy and lactation women; 3) with severe cardiac insufficiency, liver and kidney (detection index exceeded the upper limit of the normal value of 1.5 times or creatinine clearance rate ml/ <60 minutes) dysfunction; 4) immune function defects (such as leukemia, cancer patients, etc.), or in the past 3 months, the use of immunosuppressive agents or corticosteroids; 5) allergy refers to more than two kinds of medicine or food allergy or of famciclovir or penciclovir or the drug allergy test known component; 6) the area of the cranial nerve in the area of herpes zoster or anal, genital herpes zoster; 7) manifested as bleeding (hemorrhagic zoster), suppurative gangrene (gangrenous zoster), extensive varicella rash (disseminated herpes zoster); 8) skin infection, appear pustular ulcer; 9) patients with mental illness or non self insight; 10) in the past 3 months to participate in clinical trials; 11) the investigator think that is not suitable to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
Acute pain intensity;The disappearance time of acute phase pain;

Secondary

MeasureTime frame
The remission time of pain;The time of scab;The time of decrustation;Diseade treatment effect;Use of analgesics at the end of treatment;The incidence of PHN at 4 weeks and 8 weeks after the end of treatment;

Countries

China

Contacts

Public ContactDongmei Zhou

Beijing Hospital of Traditional Chinese Medicine

52176857@163.com+86 010-52176857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026